NCT01430455

Tranylcypromine Treatment of Bipolar Depression

• Status: Completed
• Phase: Phase 4
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: New York State Psychiatric Institute · Academic / Other
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Not accepted

Summary

This study seeks to investigate whether tranylcypromine (Parnate®) might be an effective treatment of bipolar depression. New treatments are needed, as there is little evidence that standard antidepressants are effective in treating this condition, and the two antipsychotic medications that have indications for bipolar depression can cause substantial side effects. This study will focus specifically on currently depressed outpatients having a bipolar history for whom at least one standard antidepressant medication was ineffective. Patients will be treated openly with tranylcypromine for 8-10 months, depending on treatment response.

Conditions

• Bipolar Disorder I or II

Interventions

Type	Name	Description
DRUG	Tranylcypromine	Tranylcypromine, between 10 mg/day and 120 mg/day throughout 16 week study

Timeline

• Start date: 2011-11-01
• Primary completion: 2014-02-01
• Completion: 2014-09-01
• First posted: 2011-09-08
• Last updated: 2018-03-15
• Results posted: 2018-03-15

Locations

1 site across 1 country: United States